Published in Medical Letter on the CDC and FDA, June 29th, 2003
FDA Commissioner Mark McClellan, MD, PhD, and NCI Director Andrew von Eschenbach, MD, said that they will establish a multipart Interagency Agreement to enhance the efficiency of clinical research and the scientific evaluation of new cancer medications. The planned agreement, announced formally at meeting of the American Society of Clinical Oncology in Chicago,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA